Antibody-based therapeutics have transformed the treatment landscape in recent decades, providing remarkable successes against a multitude of different diseases, particularly in oncology, autoimmunity and chronic inflammatory diseases. With over 180 approvals in recent decades, the field has exploded and continues to evolve with improved engineering and design to enable clinical advances.  Looking to the future, artificial intelligence (AI) has the potential, albeit largely unrealized, to transform antibody discovery and optimization even further to address remaining challenges in the field.

This meeting will explore the future of antibody engineering and AI applications in the generation of antibody drugs, identifying opportunities and challenges with emerging antibody-based modalities.  The program will explore novel approaches including antibody-conjugates with novel payloads such as oligonucleotides and conditional activation of antibodies for example to improve therapeutic index for cancer. Strategies for harnessing the immune system more optimally with bispecific and multispecific antibodies as well as through and engineered effector functions will be discussed. Participants will gain a broad understanding of cutting-edge approaches that will define the future of the field in years to come.  This meeting will bring together scientists across a broad range of disciplines involved in designing and delivering antibody drugs. By bridging basic, translational, clinical and industry science we will catalyze interdisciplinary collaborations and innovations required to tackle the most critical challenges with antibody drugs.

Additionally, this conference will be co-located with the Keystone Symposium on “Emerging Cell Therapies” to enable cross-pollination of ideas, tools and technologies towards bioengineering the next-generation of transformational therapeutics.